Bryostatin 1 enhances lymphokine activated killer sensitivity and modulates the beta 1 integrin profile of cultured human tumor cells.
Bryostatin 1 interferes with protein kinase C (PKC) signaling which is involved in the activation of human and murine cytotoxic T lymphocytes, and in the growth and differentiation of tumor cells. Bryostatin 1 has immunomodulating and antitumor properties as demonstrated by preclinical and clinical studies. Here we report that bryostatin 1 increases the susceptibility to lymphokine activated killers and modifies the pattern of beta 1 integrin expression of human tumor cells. On the basis of these results the use of bryostatin 1 in combination with immunostimulating cytokines such as interleukin-2 in the treatment of human cancer is suggested.
Correale
P
P
Dipartimento di Endocrinologia ed Oncologia Molecolare e Clinica, Università Federico II, Napoli, Italy.
Caraglia
M
M
Fabbrocini
A
A
Guarrasi
R
R
Pepe
S
S
Patella
V
V
Marone
G
G
Pinto
A
A
Bianco
A R
AR
Tagliaferri
P
P
D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000970:Antineoplastic Agents / Q000494:pharmacology*; D054713:Bryostatins; D006801:Humans; D019012:Integrin beta1; D016023:Integrins / Q000032:analysis*; D015979:Killer Cells, Lymphokine-Activated / Q000187:drug effects*; D007783:Lactones / Q000494:pharmacology*; D018942:Macrolides; D014407:Tumor Cells, Cultured
D000276:Adjuvants, Immunologic; D000970:Antineoplastic Agents; D054713:Bryostatins; D019012:Integrin beta1; D016023:Integrins; D007783:Lactones; D018942:Macrolides; C046785:bryostatin 1